Tim Kutzkey Purchases 5,523 Shares of Surrozen (NASDAQ:SRZN) Stock

Surrozen, Inc. (NASDAQ:SRZN) Director Tim Kutzkey bought 5,523 shares of the business’s stock in a transaction on Wednesday, January 14th. The shares were acquired at an average price of $19.99 per share, for a total transaction of $110,404.77. Following the completion of the transaction, the director owned 999,429 shares in the company, valued at approximately $19,978,585.71. This trade represents a 0.56% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Tim Kutzkey also recently made the following trade(s):

• On Tuesday, January 13th, Tim Kutzkey purchased 12,470 shares of Surrozen stock. The shares were acquired at an average price of $19.80 per share, with a total value of $246,906.00.
• On Tuesday, January 6th, Tim Kutzkey purchased 15,100 shares of Surrozen stock. The shares were acquired at an average cost of $19.89 per share, with a total value of $300,339.00.
• On Friday, December 5th, Tim Kutzkey acquired 30,884 shares of Surrozen stock. The stock was acquired at an average cost of $19.54 per share, for a total transaction of $603,473.36.
• On Thursday, December 4th, Tim Kutzkey bought 5,266 shares of Surrozen stock. The shares were acquired at an average cost of $17.35 per share, with a total value of $91,365.10.
• On Thursday, November 13th, Tim Kutzkey purchased 315,457 shares of Surrozen stock. The stock was bought at an average cost of $12.65 per share, for a total transaction of $3,990,531.05.

Surrozen Stock Performance

Shares of NASDAQ:SRZN remained flat at $20.00 during midday trading on Thursday. The stock had a trading volume of 28,721 shares, compared to its average volume of 83,852. Surrozen, Inc. has a 1-year low of $5.90 and a 1-year high of $24.94. The business has a 50 day moving average of $18.38 and a two-hundred day moving average of $13.80. The company has a market cap of $171.40 million, a PE ratio of -0.90 and a beta of 0.58.

Surrozen (NASDAQ:SRZN) last released its earnings results on Friday, November 7th. The company reported ($3.61) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($2.44). Surrozen had a negative net margin of 2,909.10% and a negative return on equity of 4,055.04%. The company had revenue of $0.98 million during the quarter. On average, sell-side analysts forecast that Surrozen, Inc. will post -8.49 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on SRZN. Weiss Ratings restated a “sell (d-)” rating on shares of Surrozen in a report on Wednesday, October 8th. Lifesci Capital raised shares of Surrozen to a “strong-buy” rating in a research report on Thursday, November 13th. Finally, Wall Street Zen upgraded shares of Surrozen to a “sell” rating in a research report on Friday, November 28th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Stempoint Capital LP increased its position in shares of Surrozen by 185.1% during the second quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock worth $6,138,000 after acquiring an additional 445,713 shares in the last quarter. Braidwell LP acquired a new position in Surrozen in the 2nd quarter worth $1,252,000. Millennium Management LLC acquired a new position in Surrozen in the 3rd quarter worth $1,414,000. Schonfeld Strategic Advisors LLC bought a new position in Surrozen during the 3rd quarter worth about $889,000. Finally, Armistice Capital LLC acquired a new stake in shares of Surrozen in the 2nd quarter valued at about $536,000. Institutional investors and hedge funds own 66.57% of the company’s stock.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.